PI3K signalling: the path to discovery and understanding

Bart Vanhaesebroeck1, Len Stephens, Phillip Hawkins

  • 1Centre for Cell Signalling, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom. bart.vanh@qmul.ac.uk

Insights

Phosphoinositide 3-kinases (PI3Ks) research has evolved significantly, identifying PI3K inhibitors as key targets for cancer and inflammation. Discoveries include PI3K-dependent networks and regulators of cell growth.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Phosphoinositide 3-kinases (PI3Ks) research has advanced over two decades.
  • PI3Ks are implicated in growth factor signaling, GPCRs, and oncogene products.
  • PI3K inhibitors are now clinical targets for cancer and inflammation.

Purpose of the Study:

  • To review major discoveries in the phosphoinositide 3-kinase (PI3K) field.
  • To highlight the progression of PI3K research from basic enzymology to therapeutic applications.

Main Methods:

  • Literature review of key PI3K discoveries.
  • Analysis of PI3K-dependent signaling networks.
  • Identification of critical protein and domain players.

Main Results:

  • PI3K's role in cellular processes is well-defined.
  • Discovery of phosphoinositide-binding domains (PH, PX, FYVE) in lipid signaling.
  • Identification of PTEN, AKT, and mTOR as crucial regulators.

Conclusions:

  • PI3K research has yielded significant insights into cell growth and disease.
  • PI3K pathways represent important targets for therapeutic intervention in cancer and inflammation.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...